호흡기 질환 유전자 검사 시장 - 세계 및 지역별 분석 : 제품별, 질병 유형별, 기술별, 형질 유형별, 연령대별, 최종사용자별, 국가별 분석 : 분석과 예측(2023-2033년)

Respiratory diseases continue to be a global health concern, with a significant impact on patient well-being and healthcare systems. Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions. This report provides an in-depth analysis of the global and regional trends in the respiratory disease genetic testing market, offering insights into market size, growth trends, regional disparities, and the impact of genetics on respiratory disease diagnostics and treatment.

Introduction

Respiratory diseases represent a diverse group of disorders, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and interstitial lung diseases, among others. The role of genetics in respiratory disease development and progression has become increasingly evident, leading to the growing importance of genetic testing in diagnosis, treatment, and prevention.

Market Overview

This section provides an overview of the global respiratory disease genetic testing market, including market size, growth trends, and key drivers.

Market Size and Growth

• Factors contributing to this growth include the rising prevalence of respiratory diseases, advances in genetic testing technologies, and increasing awareness of personalized medicine.

Global Trends

• Personalized Medicine: Genetic testing allows healthcare providers to tailor treatment plans to an individual's genetic profile, enhancing treatment efficacy and minimizing adverse effects.

• Targeted Therapies: Genetic testing results are guiding the development of targeted therapies for specific respiratory diseases, leading to more effective and precise treatment options.

• Genome-wide Association Studies (GWAS): Ongoing GWAS are identifying novel genetic markers associated with respiratory diseases, expanding our understanding of their genetic basis.

Impact on Diagnosis and Treatment

Genetic testing has a significant impact on the diagnosis and treatment of respiratory diseases.

• Early Diagnosis: Genetic testing enables early identification of individuals at risk, allowing for timely intervention and personalized treatment plans.

• Treatment Selection: Genetic profiles help clinicians choose the most suitable therapies, minimizing trial-and-error approaches and improving patient outcomes.

• Family Screening: Genetic testing supports family screening to identify genetic predispositions to respiratory diseases, allowing for preventative measures.

Challenges and Opportunities

This section outlines the challenges and opportunities within the respiratory disease genetic testing market.

Challenges

• Ethical and Privacy Concerns: The ethical use of genetic data and privacy concerns continue to be important considerations.

• Access to Testing: Disparities in access to genetic testing services exist, affecting the equitable provision of care.

Opportunities

• Advancements in Technology: Ongoing technological advancements are improving the accuracy and affordability of genetic testing.

• Integration with Healthcare Systems: Integration with electronic health records and healthcare systems is streamlining the use of genetic information in clinical practice.

Table of Contents

1. Product Definition

• 1.1. Inclusion and Exclusion

2. Market Scope

• 2.1. Scope of Work
• 2.2. Key Questions Answered in the Report

3. Research Methodology

• 3.1. Global Respiratory Disease Genetic Testing Market: Research Methodology
• 3.2. Data Sources
  • 3.2.1. Primary Data Sources
  • 3.2.2. Secondary Data Sources
• 3.3. Market Estimation Model
• 3.4. Criteria for Company Profiling

4. Global Respiratory Disease Genetic Testing Market: Overview

• 4.1. Market Definition
• 4.2. Market Footprint and Growth Potential
• 4.3. Future Potential
• 4.4. Genetic Surfactant Related Disorders
• 4.5. Pulmonary Phenotypes and Related Genes
• 4.6. Practical Issues of Genetic Testing for Respiratory Diseases
• 4.7. Advantages and Disadvantages of Different Genetic Sequencing Approaches

5. Global Respiratory Disease Genetic Testing Market: Industry Analysis

• 5.1. Overview
• 5.2. Legal and Regulatory Framework
  • 5.2.1. Overview
  • 5.2.2. Regulatory Framework in the U.S.
  • 5.2.3. Regulatory Framework in the European Union
  • 5.2.4. Regulatory Framework in Asia
• 5.3. Product Pipeline Analysis
  • 5.3.1. Overview
  • 5.3.2. By Companies
  • 5.3.3. By Developmental Phase
• 5.4. Funding Scenario (2019-2022)
  • 5.4.1. Overview
  • 5.4.2. Institutional vs. Academic Funding
• 5.5. Patent Analysis
  • 5.5.1. Overview
  • 5.5.2. By Country
  • 5.5.3. By Year

6. Global Respiratory Disease Genetic Testing Market: Dynamics

• 6.1. Overview
• 6.2. Impact Analysis
• 6.3. Market Drivers
• 6.4. Market Restraints
• 6.5. Market Opportunities

7. Global Respiratory Disease Genetic Testing Market: Competitive Landscape

• 7.1. Overview
• 7.2. Synergistic Activities
• 7.3. Product Launches and Enhancements
• 7.4. Product Approvals
• 7.5. Mergers and Acquisitions
• 7.6. Business Expansion and Other Activities
• 7.7. Market Share Analysis, By Company (2022)
• 7.8. Growth Share Analysis
  • 7.8.1. By Application
  • 7.8.2. By Technology

8. Global Respiratory Disease Genetic Testing Market (by Offerings), 2022-2033, ($Million)

• 8.1. Overview
• 8.2. Products
  • 8.2.1. Kits and Consumables
• 8.3. Services
• 8.4. Others

9. Global Respiratory Disease Genetic Testing Market (by Disease Type), 2022-2033, ($Million)

• 9.1. Overview
• 9.2. COPD (Alpha-1-antitrypsin (AAT)
• 9.3. Cystic Fibrosis (CF)
• 9.4. Diffuse Lung Disease/Surfactant Dysfunction
  • 9.4.1. RHD (Respiratory Distress Syndrome)
  • 9.4.2. PPHN (Persistent Pulmonary Hypertension of the Newborn)
• 9.5. Interstitial lung disease
• 9.6. Pulmonary Arterial Hypertension
• 9.7. Pulmonary Hypoplasia
• 9.8. Primary Ciliary Dyskinesia
• 9.9. Other Diseases (BPD)

10. Global Respiratory Disease Genetic Testing Market (by Technology), 2022-2033, ($Million)

• 10.1. Overview
• 10.2. PCR
• 10.3. NGS
  • 10.3.1. Whole Genome Sequencing
  • 10.3.2. Whole Exome Sequencing
• 10.4. Others (Targeted Sequencing, Karyotyping, and FISH)

11. Global Respiratory Disease Genetic Testing Market (by Trait Type), 2022-2033, ($Million)

• 11.1. Overview
• 11.2. Inherited Trait
• 11.3. Acquired Trait

12. Global Respiratory Disease Genetic Testing Market (by Age Group), 2022-2033, ($Million)

• 12.1. Overview
• 12.2. Children Age Group
• 12.3. Adult Age Group

13. Global Respiratory Disease Genetic Testing Market (by End User), 2022-2033, ($Million)

• 13.1. Overview
• 13.2. Hospital Laboratories
• 13.3. Diagnostics Laboratories
• 13.4. Genetic Testing Laboratories
• 13.5. Research Laboratories
• 13.6. Other End User

14. Global Respiratory Disease Genetic Testing Market (by Region), 2022-2033, ($Million)

• 14.1. Overview
• 14.2. Growth Potential Analysis (by Country)
• 14.3. North America
  • 14.3.1. Key Dynamics
  • 14.3.2. U.S.
    • 14.3.2.1. By Application
    • 14.3.2.2. By Technology
  • 14.3.3. Canada
    • 14.3.3.1. By Application
    • 14.3.3.2. By Technology
• 14.4. Europe
  • 14.4.1. Key Dynamics
  • 14.4.2. Italy
    • 14.4.2.1. By Application
    • 14.4.2.2. By Technology
  • 14.4.3. France
    • 14.4.3.1. By Application
    • 14.4.3.2. By Technology
  • 14.4.4. Russia
    • 14.4.4.1. By Application
    • 14.4.4.2. By Technology
  • 14.4.5. Germany
    • 14.4.5.1. By Application
    • 14.4.5.2. By Technology
  • 14.4.6. U.K.
    • 14.4.6.1. By Application
    • 14.4.6.2. By Technology
  • 14.4.7. Spain
    • 14.4.7.1. By Application
    • 14.4.7.2. By Technology
  • 14.4.8. Rest-of-Europe
• 14.5. Asia-Pacific
  • 14.5.1. Key Dynamics
  • 14.5.2. China
    • 14.5.2.1. By Application
    • 14.5.2.2. By Technology
  • 14.5.3. Japan
    • 14.5.3.1. By Application
    • 14.5.3.2. By Technology
  • 14.5.4. India
    • 14.5.4.1. By Application
    • 14.5.4.2. By Technology
  • 14.5.5. Australia
    • 14.5.5.1. By Application
    • 14.5.5.2. By Technology
  • 14.5.6. Singapore
    • 14.5.6.1. By Application
    • 14.5.6.2. By Technology
  • 14.5.7. South Korea
    • 14.5.7.1. By Application
    • 14.5.7.2. By Technology
  • 14.5.8. Rest-of-Asia-Pacific
• 14.6. Latin America
  • 14.6.1. Key Dynamics
  • 14.6.2. Brazil
    • 14.6.2.1. By Application
    • 14.6.2.2. By Technology
  • 14.6.3. Mexico
    • 14.6.3.1. By Application
    • 14.6.3.2. By Technology
  • 14.6.4. Rest-of-Latin America
• 14.7. Rest-of-the-World
  • 14.7.1. Key Dynamics
  • 14.7.2. Middle East and Africa
    • 14.7.2.1. By Application
    • 14.7.2.2. By Technology
  • 14.7.3. Rest-of-Rest-of-the-World

15. Company Profiles

• 15.1. Overview
• 15.2. 23andMe, Inc.
• 15.3. Centogene A.G.
• 15.4. GeneDx, Inc.
• 15.5. Invitae Corporation
• 15.6. Color Genomics
• 15.7. Myriad Genetics
• 15.8. Medicover Genetics
• 15.9. Blueprint Genetics
• 15.10. Prevention Genetics
• 15.11. Quest Diagnostics
• 15.12. Genesis Genetics
• 15.13. ARUP Laboratories
• 15.14. EGL Genetic Diagnostics
• 15.15. Laboratory Corporation of America Holdings (LabCorp)